Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21134594 | 0.89 | CYP2D6 (0.33) | PTGS1PTGS2 | |
| SCHEMBL10556479 | 0.86 | CYP1A2 (0.40) | CYP1A2LMNAMAPK1HTTTLR4 | |
| SCHEMBL10556466 | 0.86 | CYP1A2 (0.40) | CYP1A2LMNAMAPK1HTTTLR4 | |
| SCHEMBL10556455 | 0.86 | CYP1A2 (0.40) | CYP1A2LMNAMAPK1HTTTLR4 | |
| SCHEMBL10557126 | 0.82 | CYP1A2 (0.35) | CYP1A2LMNAMAPK1HTT | |
| SCHEMBL10557117 | 0.82 | CYP1A2 (0.35) | CYP1A2LMNAMAPK1HTT | |
| SCHEMBL10557122 | 0.82 | CYP1A2 (0.35) | CYP1A2LMNAMAPK1HTT | |
| SCHEMBL17835277 | 0.80 | CYP2D6 (0.31) | — | |
| SCHEMBL11903679 | 0.78 | CYP1A2 (0.48) | CYP1A2LMNAMAPK1HTTTLR4 | |
| SCHEMBL10551250 | 0.75 | TLR4 (0.37) | TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2320887-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LIGNANS AND THEIR DERIVATIVES FOR TREATING HYPERPLASTIC DISEASES | UNIVERSITÄT INNSBRUCK (AT) | 2016-10-26 | — | — | EP | disclosed |